Skip to main content
Clinical Trials/NCT01813240
NCT01813240
Unknown
Phase 2

Prevention of Imminent Paralysis Following Spinal Cord Trauma or Ischemia by Minocycline: A Multi-center Study in Israel With IDF Primary Care Involvement

Hadassah Medical Organization1 site in 1 country444 target enrollmentMay 2013

Overview

Phase
Phase 2
Intervention
placebo
Conditions
Spinal Tumors, Trauma Patients, Minocycline.
Sponsor
Hadassah Medical Organization
Enrollment
444
Locations
1
Primary Endpoint
Efficacy of administrating minocycline in minimizing the neurological damage among acute spinal cord injury patients and spinal cord tumors (primary and metastases) patients
Last Updated
13 years ago

Overview

Brief Summary

Spinal cord trauma and the consequent paraplegia are possibly among the most devastating injuries in soldiers and during spine surgery, and are significant in the medical, social and financial aspects. Limited mobility, the need for assistance in all human activities, shame, and many medical complications related directly to the neural deficits make paraplegia an important target for prevention. Our study will evaluate the efficacy of Minocycline in two different groups:

  1. Minimizing the neurological damage among trauma patients.
  2. Preventing neurological damage through operation in spinal tumors patients.

2.OBJECTIVES

The primary objectives of the trial are to determine:

  1. Efficacy of administrating minocycline in minimizing the neurological damage among acute spinal cord injury patients and spinal cord tumors (primary and metastases) patients?
  2. Efficacy of administrating minocycline at changing the natural history and rehabilitation of spinal cord trauma patients.
  3. Safety of applying minocycline in spinal cord injuries patients and spinal cord tumors?
Registry
clinicaltrials.gov
Start Date
May 2013
End Date
April 2015
Last Updated
13 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Benjamin Drenger

Associate Professor of Anesthesia, Director, Orthopedic Anesthesia,

Hadassah Medical Organization

Eligibility Criteria

Inclusion Criteria

  • Trauma patients with incomplete spinal cord syndromes related to fractures, dislocations, blunt trauma (central cord syndrome).
  • Inclusion Criteria:
  • Patients with incomplete spinal cord syndromes related to fractures, dislocations, blunt trauma (central cord syndrome).
  • Ages: 18 to 65
  • Males - including those involved in active military duty.
  • Females - of child-bearing potential who have a negative pregnancy test (hCG urine) within 72 hours of informed consent. Pregnant women will be excluded from the study.

Exclusion Criteria

  • Complete cord transection, severe head injury, coma, or other disease of the CNS, and spinal injury diagnosed later than 24 hours.
  • Pregnant women (minocycline can cause fetal harm) and children.
  • Lower extremity fractures, mildly reduced consciousness and frail cognitive status will not be considered for exclusion.
  • Patients who will not be enrolled will be listed and reason for non inclusion will be recorded.
  • Spinal tumors:
  • Inclusion Criteria:
  • Intrathecal extramedullary tumors, vertebral metastases or primary vertebral tumors causing cord compression with or without incomplete cord syndrome.
  • Exclusion criteria:
  • 1.Intramedullary tumors or tumors causing complete cord syndrome

Arms & Interventions

Placebo, Spinal cord tumors, quality of life

Intervention: placebo

Minocycline, Spinal Tumor patients, quality of life

Intervention: Minocycline

Minocycline, Trauma patuents, quality of life

Intervention: Minocycline

Placebo, Trauma patients, quality of life

Intervention: placebo

Outcomes

Primary Outcomes

Efficacy of administrating minocycline in minimizing the neurological damage among acute spinal cord injury patients and spinal cord tumors (primary and metastases) patients

Time Frame: six months

The Efficacy will be evaluated using the following measures: 1. ASIA SCORE - We will compare the results before administrating the study medication and after six months of follow up. The ASIA score will be the Primary Efficacy Endpoint. 2. The Spinal Cord Independence Measure and Functional Independence Measure outcome scales. 3. Objective reduction in lesion size by imaging modalities

Secondary Outcomes

  • Efficacy of administrating minocycline at changing the natural history and rehabilitation of spinal cord trauma patients.(six months)
  • Safety of applying minocycline in spinal cord injuries patients and spinal cord tumors?(six months)

Study Sites (1)

Loading locations...

Similar Trials